GAMMA KNIFE MARKET ANALYSIS

Gamma Knife MarketSize and Trends

The global gamma knife market is estimated to be valued at US$ 239.1 billion in 2023 and is expected to exhibit a CAGR of 5.4% during the forecast period (2023-2030).

Global Gamma Knife Market– Drivers

• Increasing inorganic growth activities such as acquisition by market players: Increasing inorganic growth activities such as acquisition by market players are expected to propel the growth of the global gamma knife market over the forecast period. For instance, in February 2021, Fujitsu Laboratories, Ltd., a technology equipment and services company, collaborated with researchers at the University of Toronto (U of T) for the development of a technology for dramatically streamlining the creation of radiation treatment plans for Gamma Knife radiosurgery. This leveraging Fujitsu’s quantum-inspired computing technology, the Digital Annealer, which rapidly solves combinatorial optimization problems.

Global Gamma Knife Market Segmentation:

The global gamma knife market report is segmented by indication, by anatomy, by end user, and by region.

• By indication, the market is segmented into brain metastasis, arteriovenous malformation (AVM), trigeminal neuralgia, and others. Out of which, brain metastatis is expected to hold a dominant position in the global gamma knife market during the forecast period, and this is attributed to the increasing use for the treatment of brain metastatis.
• By application, the market is segmented into head, neck, and others. Out of which, the head segment is expected to dominate the market over the forecast period, and this is attributed to increasing neurologic disorders.
• By end user, the market is segmented into hospital clinics, and ambulatory surgical centers. Out of which, hospital is expected to dominate the market over the forecast period, and this is attributed to the prompt treatment that can lead to proper recovery.
• Among all the segments, the brain metastases segment is expected to dominate the market over the forecast period, and this is attributed to constantly increasing collaboration by market players. For instance, in April 2022, Elekta collaborated with GE Healthcare, a manufacturing company, for the commercialization of radiation oncology. It provides hospitals with a comprehensive offering across imaging and treatment for cancer patients requiring radiation therapy for the treatment of cancer.